SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing a surge, driven by factors like potential Fed rate cuts and renewed focus from Elon Musk. Community discussions revolve around the stock potentially reaching $400 soon, with some anticipating a gamma squeeze. Others caution about overvaluation and potential pullbacks, highlighting the stock's volatile nature.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated discussions and political rhetoric following a shooting involving conservative activist Charlie Kirk. The community is divided, with some users trading accusations related to political affiliations and alleged radicalization, while others are focusing on the Epstein files and calling for their release. Broader discussions touch upon gun control, media influence, and the state of political discourse.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates a potential ETF launch, though some traders suggest the launch may be delayed. Bullish sentiment is fueled by speculation of increased institutional investment, with some setting targets and calling for a push to new highs. Despite the optimism, some traders caution against a potential "sell the news" event.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending due to anticipation surrounding upcoming data release for their Phase 3 trial, with community members actively discussing potential outcomes and comparing the situation to previous short squeeze events like GME. Bullish sentiment centers around the belief in positive data and a potential short squeeze, while bears, including figures like Martin Shkreli, express skepticism and anticipate a negative outcome. The discussion includes technical analysis, potential price targets, and the overall risk/reward profile of this binary event.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking discussions about potential market capitalization changes and future news catalysts. The community is actively debating the implications of this investment, alongside speculation about upcoming events and their effect on the stock's price. Some traders are also highlighting the stock's low float and high short interest as potential drivers for significant price movement.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid reports the Trump administration may pull COVID-19 vaccines from the market, sparking intense debate about the future of mRNA technology and its impact on the company. The community is discussing the potential for a short squeeze, while weighing the significance of pipeline developments against political and regulatory headwinds.  Some traders are also expressing concerns about the potential impact from negative public sentiment surrounding vaccines.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its Oxford Ionics acquisition, sparking discussions about the deal's implications and potential synergies. Community members are debating whether the stock is overvalued and if it can maintain its gains, while also weighing the broader prospects of the quantum computing sector. Some traders are eyeing shorting opportunities, while others express bullish sentiment, anticipating further catalysts.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around potential links between COVID vaccines and child deaths, sparking debates over vaccine safety and potential liabilities. The community is weighing the impact of these concerns against the broader context of Pfizer's pipeline and dividend yield, with some calling for leadership changes. Some are considering the potential rotation to big pharma as the market corrects.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition by Paramount Skydance, driving significant interest and trading volume. Community discussions revolve around the potential buyout price, strategic implications of combining content libraries, and possible bidding war scenarios involving other major players like Apple and Amazon. Traders are weighing the potential synergies, debt considerations, and the possibility of a bidding war that could significantly impact the stock's valuation.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending as the community debates a recent pullback following a significant run-up, with discussions around profit-taking, short positions, and potential support levels. Some traders are pointing to a new CEO and potential layoffs as key factors, while others remain bullish, anticipating a continued upward trend and potential short squeeze. The stock's high volatility and recent price action are fueling active discussions among investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investing.com’s stocks of the week

Investing.com -- Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns.

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharma-experimental-drug-yields-weight-reduction-in-brain-damage-related-obesity/chFy2A1R5KT">encouraging Phase 2 results</a> for bivamelagon, its experimental oral treatment for hypothalamic obesity.LeerinkLeerink bumped its target to $102 from $88, keeping an 'Outperform' rating on the stock.&nbsp;The firm updated its estimates following the company's disclosure of Phase 2 data for bivamelagon, which it described as “close to a best-case scenario.”&nbsp;Leerink said investor feedback has been highly positive regarding efficacy, with minimal concerns on safety.NeedhamNeedham increased its price target to $95 from $72 and kept a 'Buy' rating.&nbsp;The firm raised its probability of success (PoS) for the bivamelagon program to 70% from 40% based on the Phase 2 results and lowered its discount rate in its discounted cash flow (DCF) model to 8% from 9.5% to reflect reduced overall risk.&nbsp;Needham added that, aside from some manageable exceptions, the tolerability profile for bivamelagon looks better than&nbsp;that of setmelanotide.Morgan Stanley&nbsp;Morgan Stanley lifted its price target to $95 from $80 and maintained an 'Overweight' rating.&nbsp;The firm noted that the Phase 2 data indicated BMI reductions above the 10% threshold, in the range of setmelanotide, with an improved profile.&nbsp;Morgan Stanley stated that this supports the advancement of bivamelagon into Phase 3 trials, which are expected in the first half of 2026.&nbsp;The firm also said early data confirm the potential for bivamelagon to expand or extend Rhythm’s opportunity in hypothalamic obesity.BofABofA raised its price target to $95 from $73 and kept a 'Buy' rating.&nbsp;The firm cited the positive topline results for bivamelagon and said the data suggest an efficacy profile similar to setmelanotide, but with more convenient once-daily oral dosing.StifelStifel raised its target to $123 from $94 and maintained a 'Buy' rating.&nbsp;The firm cited the Phase 2 data for bivamelagon and stated the treatment is now “derisked” on efficacy and “mostly derisked” on safety.&nbsp;Stifel said Rhythm now has an opportunity to extend the duration of its MC4R franchise beyond 2040.Wells FargoWells Fargo increased its price target to $129 from $91 and kept an 'Overweight' rating.&nbsp;The firm said the Phase 2 data are a “key inflection” for Rhythm’s MC4R franchise and that the stock should “trade up meaningfully.”&nbsp;Wells estimates the data adds approximately $35 per share in value and significantly increases the probability of success and durability for Rhythm’s MC4R franchise into the mid-2040s.On Stocktwits, retail sentiment for Rhythm was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/RYTM">Rhythm’s stock</a> has risen 48.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Analysts from Wells Fargo, Stifel, and others raised their targets on Rhythm Pharma (RYTM) following the release of strong BMI reduction data for bivamelagon/ Photo credit: Getty Images

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing encouraging Phase 2 results for bivamelagon, its experimental oral treatment for hypothalamic obesity.

Equity

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and clinically meaningful reductions in body mass index (BMI) in patients with acquired hypothalamic obesity in a mid-stage trial.<a href="https://stocktwits.com/symbol/RYTM">Rhythm’s shares</a> were trading 31% higher at the time of writing.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-oral-mc4r-agonist-bivamelagon">said</a> that Bivamelagon achieved as much as a 9.3% reduction from baseline in body mass index at 14 weeks of treatment. Patients also reported meaningful reduction in their ‘most’ hunger scores at 14 weeks on therapy as compared to placebo, the company said.CEO David Meeker said that the company is excited by the results, which suggest Bivamelagon has the potential to treat patients with acquired hypothalamic obesity. Rhythm in-licensed Bivamelagon from LG Chem, Ltd in January 2024.Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain, which most frequently follows the growth or surgical removal of craniopharyngioma, astrocytoma, or other rare brain tumors.Patients experience accelerated weight gain, a reduction in energy expenditure, and hyperphagia (a chronic pathological condition characterized by insatiable hunger, impaired satiety, and persistent abnormal food-seeking behaviors), leading to severe obesity within six to 12 months following tumor resection or other injury.Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. The company is also refining the formulation of Bivamelagon, potentially to improve tolerability ahead of initiating a late-stage trial, as one of the 28 patients in the mid-stage study discontinued therapy due to rectal bleeding.Rhythm estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S., 5,000 to 8,000 people living with hypothalamic obesity in Japan, and 3,500 to 10,000 people living with hypothalamic obesity in the E.U.On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_09_at_11_39_04_AM_png_f718a4e952.webp" alt="RYTM's Sentiment Meter and Message Volume as of 11:39 a.m. ET on July 9, 2025 | Source: Stocktwits" width="623" height="67"><figcaption>RYTM's Sentiment Meter and Message Volume as of 11:39 a.m. ET on July 9, 2025 | Source: Stocktwits</figcaption></figure>RYTM stock is up by about 52% this year and by about 90% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-slaps-30-tariff-on-iraq-says-its-less-than-what-is-needed/chFy2f8R5Kb">Trump Slaps 30% Tariff On Iraq, Says It’s ‘Less Than What Is Needed’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Shares of Rhythm Pharmaceuticals Inc. (RYTM) traded 14% higher on Monday noon after the company<a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial"> announced</a> positive results from a trial of setmelanotide therapy in the treatment of acquired hypothalamic obesity and subsequent price target upgrades.The biopharmaceutical company announced positive results from its phase 3 trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for treating acquired hypothalamic obesity.Acquired hypothalamic setmelanotide is a rare form of obesity resulting from damage to the hypothalamus, resulting in accelerated weight gain and insatiable hunger.The company estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S.The company said that it observed a statistically significant and highly clinically meaningful reduction in body mass index (BMI) with setmelanotide in both adult and pediatric patients as compared to those administered with a placebo.CEO David Meeker said that the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.Bank of America subsequently upgraded the pharmaceutical company’s rating to ‘Buy’ from ‘Neutral’ while also hiking the price target to $63, up from $60.BofA opined that the company’s setmelanotide is "likely approvable" based on recent data provided by the company.The recent pullback in the shares offers "additional upside opportunity", the analyst told investors, according to TheFly.Wells Fargo also raised its price target on the company to $91 from $80 while keeping an “Overweight” rating on the shares.The firm, which believes that the shares should be trading higher on the trial data, said that the trial results are “solid” and near the bull case.Wells sees Rhythm trading to over $100 per share by the end of 2025.On Stocktwits, retail sentiment about RYTM jumped higher in the ‘extremely bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:1302/294;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_2_11_21_PM_png_23de55ab36.webp" alt="RYTM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 7, 2025 | Source: Stocktwits" width="1302" height="294"><figcaption>RYTM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RYTM">RYTM shares</a> are down by over 11% this year but up by nearly 28% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-china-with-50-additional-tariffs/chf1CZ6Rb7r">Trump Threatens China With 50% Additional Tariffs If Xi Jinping’s Administration Fails To Lift Duties By Tuesday, Warns Termination Of Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish 

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. 

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. 

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts

Latest Ratings for RYTM
 DateFirmActionFromTo Mar 2022Canaccord GenuityMaintainsBuy Mar 2022NeedhamMaintainsBuy Feb 2022NeedhamMaintainsBuy
 View More Analyst Ratings for RYTM

 View the...

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$GEMI IPO day is upon us, how are you playing it?

Stocktwits

Gemini Space Station

 IPO day is upon us, how are you playing it?

RYTM
Rhythm Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RYTM News

RYTM Rhythm Pharmaceuticals Inc.